The transdermal drug delivery system (TDDS) is a cutting-edge method whose primary goals are to increase patient compliance, sustain medication release, and increase drug bioavailability. Among the different kinds of transdermal patches, matrix dispersion type systems distribute the medication and polymers in a solvent, allowing the solvent to evaporate and creating a uniform drug-polymer matrix. One of the novel drug delivery methods is the medicated transdermal patch system, which applies a prescribed dosage of medication to the skin's surface and then circulates it through the skin and into the bloodstream.With an insulinindependent mechanism, canagliflozin (CFZ), a member of a new class of sodium glucose cotransporter (SGLT II) inhibitors, has been extensively utilized in the treatment of type 2 diabetic mellitus (T2DM). SGLT II is a low-capacity/high-affinity Na +/K+ co-transporter that is mostly found in the kidneys' proximal convoluted tubules (PCT). It inhibits glucose reabsorption and promotes urine excretion of glucose as a result. The current project aims to create transdermal patches containing an anti-diabetic medication that increase canagliflozin's bioavailability. Transdermal patches, permeability, solubility, moisture content, and pharmacological properties are the key words.